Impact of Genetic Targets on Cancer Therapy: Hepatocellular Cancer
- 21 November 2012
- book chapter
- Published by Springer Nature
- Vol. 779, 67-90
Abstract
Understanding cancer at the genetic level had gained significant attention over the last decade since the human genome was first sequenced in 2001. For hepatocellular carcinoma (HCC) a number of genome-wide profiling studies have been published. These studies have provided us with gene sets, based on which we can now classify tumors and have an idea about the likely clinical outcomes. In addition to that, genomic profiling for HCC has provided us a better understanding of the carcinogenesis process and identifies key steps at multiple levels (i.e. Genetics, molecular pathways) that can be potential targets for treatment and prevention. Although still an incurable disease, unresectable HCC has one proven systemic therapy, sorafenib, and many under active investigation. With advancement in technology and understanding of hepatocarcinogenesis, scientists hope to provide true personalized treatment for this disease in the near future. In this review article we discuss advances in understanding genetics and pathogenesis of HCC and the currently available and ongoing trials for targeted therapies. These emerging therapies may guide the development of more effective treatments or possibly a cure for HCC.Keywords
This publication has 105 references indexed in Scilit:
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaHepatology, 2011
- Targeted Therapies for Hepatocellular CarcinomaGastroenterology, 2011
- Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular CarcinomaGastroenterology, 2011
- Phase 1/2 study of everolimus in advanced hepatocellular carcinomaCancer, 2011
- Exploring genomic profiles of hepatocellular carcinomaMolecular Carcinogenesis, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockageJournal of Hepatology, 2010
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Heparanase: a target for drug discovery in cancer and inflammationBritish Journal of Pharmacology, 2007
- Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis†Hepatology, 2005